Beam Therapeutics Inc.
NASDAQ:BEAM
27.94 (USD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|---|---|
Revenue
| 377.709 | 60.92 | 51.844 | 0.024 | 0.018 | 0 | 0 |
Cost of Revenue
| 20.012 | 22.577 | 16.441 | 103.179 | 5.407 | 0.65 | 0.011 |
Gross Profit
| 357.697 | 38.343 | 35.403 | -103.155 | -5.389 | -0.65 | -0.011 |
Gross Profit Ratio
| 0.947 | 0.629 | 0.683 | -4,298.125 | -299.389 | 0 | 0 |
Reseach & Development Expenses
| 437.381 | 311.594 | 387.087 | 103.179 | 54.619 | 33.873 | 5.859 |
General & Administrative Expenses
| 116.813 | 87.805 | 57.222 | 29.605 | 20.553 | 11.868 | 2.021 |
Selling & Marketing Expenses
| -20.012 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 96.801 | 87.805 | 57.222 | 29.605 | 20.553 | 11.868 | 2.021 |
Other Expenses
| -437.381 | 0 | 0 | 0 | -0.071 | -10.04 | 0.378 |
Operating Expenses
| 534.182 | 399.399 | 444.309 | 132.784 | 75.172 | 45.741 | 7.88 |
Operating Income
| -176.485 | -338.479 | -392.465 | -132.76 | -75.154 | -45.741 | -7.88 |
Operating Income Ratio
| -0.467 | -5.556 | -7.57 | -5,531.667 | -4,175.222 | 0 | 0 |
Total Other Income Expenses Net
| 45.324 | 78.301 | 21.827 | -61.832 | -3.172 | -71.289 | -0.122 |
Income Before Tax
| -131.161 | -260.178 | -370.638 | -194.592 | -78.326 | -116.738 | -8.002 |
Income Before Tax Ratio
| -0.347 | -4.271 | -7.149 | -8,108 | -4,351.444 | 0 | 0 |
Income Tax Expense
| 1.366 | 3.41 | -29.278 | 61.832 | 0.116 | -70.997 | 0.5 |
Net Income
| -132.527 | -263.588 | -341.36 | -256.424 | -78.442 | -115.257 | -8.002 |
Net Income Ratio
| -0.351 | -4.327 | -6.584 | -10,684.333 | -4,357.889 | 0 | 0 |
EPS
| -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
EPS Diluted
| -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
EBITDA
| -156.473 | -401.483 | -414.301 | -64.625 | -69.236 | 16.158 | -7.369 |
EBITDA Ratio
| -0.414 | -6.59 | -7.991 | -2,692.708 | -3,846.444 | 0 | 0 |